c. weekly six times followed by biweekly three times. Procedures GDC-0941 supplier of the study were in accordance with the Declaration of Helsinki of 1964 (2008 revision) and were approved by our hospital ethics committee. A 50-year-old woman with chronic hepatitis C genotype 2a infection initiated retreatment with PEG IFN-α-2a 180 μg per week and RBV 600 mg/day in November 2010 (Fig. 3a). She had no history of blood transfusion. Approximately 2 years earlier, she had received PEG IFN-α and RBV therapy. In the previous therapy, HCV RNA became negative according to real-time polymerase chain reaction (PCR) at week 4, but the total dose of RBV was 30.6%

lower than the planned dose and HCV RNA relapsed post-treatment. The laboratory values at the start of retreatment were as follows: aspartate aminotransferase (AST), 37 IU/L; see more alanine aminotransferase (ALT), 35 IU/L;

γ-glutamyltransferase (GGT), 28 IU/L; endogenous erythropoietin, 12.0 IU/L (normal, 4.2–23.7); hemoglobin concentration, 13.4 g/dL; white blood cell count, 4000/mm3; and platelet count, 123 000/mm3. Epoetin-β was started at week 3 and administrated nine times according to the protocol, and the dose of RBV was not reduced. HCV RNA became negative at week 4, and she achieved SVR. A 64-year-old woman with chronic hepatitis C genotype 2a infection initiated PEG IFN-α-2a 180 μg per week and RBV 600 mg/day in September 2012 (Fig. 3b). At the age of 11 years, she had undergone surgery for congenital hip dislocation with transfusion. In the preceding therapy approximately 2 years earlier, HCV RNA became negative according to real-time PCR at week 8, but the total dose of RBV was reduced by 18.1% and HCV RNA relapsed post-treatment. The laboratory values at the start of retreatment were as follows: AST, 16 IU/L; ALT, 11 IU/L; GGT, 14 IU/L; erythropoietin, 8.1 IU/L; hemoglobin, 14.5 g/dL; white blood cell, 4100/mm3; and platelet, 108 000/mm3. Epoetin-β was started at week 2 and administrated nine times, and the dose of RBV was not reduced. HCV RNA became negative

at week 8, and she achieved SVR. A 68-year-old woman 上海皓元医药股份有限公司 with chronic hepatitis C genotype 2b infection started PEG IFN-α-2a 180 μg per week and RBV 600 mg/day in October 2010 (Fig. 3c). At 33 years of age, she underwent cardiac surgery for atrial septal defect closure with transfusion. In the preceding therapy approximately 4 years earlier, HCV RNA became negative according to real-time PCR at week 8, but the total dose of RBV was reduced by 19.4% and HCV RNA relapsed post-treatment. The laboratory values at the start of retreatment were as follows: AST, 32 IU/L; ALT, 52 IU/L; GGT, 16 IU/L; erythropoietin, 20.6 IU/L; hemoglobin, 14.5 g/dL; white blood cell, 5200/mm3; and platelet, 119 000/mm3. Epoetin-β was started at week 3 and administrated nine times, and the total dose of RBV was reduced only by 4.2%. HCV RNA became negative at week 4, and she achieved SVR.